Status | Study |
Active, not recruiting |
Study Name: A Phase 1b Study of Paclitaxel And Ricolinostat For The Treatment Of Gynecological Cancer Condition: Ovarian Cancer Fallopian Tube Cancer Primary Peritoneal Ca Date: 2016-01-20 Interventions: Drug: Paclitaxel Please see ar |
Completed |
Study Name: Antispasmodic Drug for Diagnosis Proximal Tubal Occlusion on Hysterosalpingography Condition: Tubal Obstruction Date: 2015-11-21 Interventions: Procedure: hysterosalpingography Starting procedure by using largest appropriate speculum for maximum ce |
Recruiting |
Study Name: A Study of Long-Term Responders on Olaparib Condition: Epithelial Ovarian Cancer Fallopian Tube Cancer Peritoneal Date: 2015-04-24 |
Not yet recruiting |
Study Name: A Study of Olaparib Prior to Surgery and Chemotherapy in Ovarian, Primary Peritoneal, and Fallopian Tube Cancer Condition: Ovarian Cancer Fallopian Tube Cancer Neoadjuvant Treatment Date: 2015-04-17 Interventions: Drug: Olaparib Other Name: Lyn |
Terminated |
Study Name: Phase 2 Trial of Regorafenib in Patients With Recurrent Ovarian, Primary Peritoneal and Fallopian Tube Cancer Condition: Ovarian Cancer Primary Peritoneal Cancer Fallopian Tube Ca Date: 2014-10-23 Interventions: Drug: regorafenib Patients will be treated with Regorafenib 160 mg (4 x 40 mg tablets) daily for 21 days |
Active, not recruiting |
Study Name: Dose-Escalation Study of Intraperitoneal (IP) Cisplatin, IV/IP Paclitaxel, IV Bevacizumab, and Oral Olaparib for Newly Diagnosed Ovarian, Primary Peritoneal, and Fallopian Tube Cancer Condition: Ovarian Cancer Primary Peritoneal Cancer Fallopian Tube Ca Date: 2014-04-22 Interventions: Drug: Paclitaxel, Drug: Bevacizumab |
Recruiting |
Study Name: Enzalutamide in Patients With Androgen Receptor Positive (AR+) Ovarian, Primary Peritoneal or Fallopian Tube Cancer and One, Two or Three Prior Therapies Condition: Advanced Epithelial Ovarian Recurrent Epithelial Ovarian F Date: 2013-10-25 Interventions: Drug: Enzalutamide All enrolled patients will be treated with enzalutamide 160mg by mouth QD. Study drug |
Completed |
Study Name: A Study of Demcizumab Plus Paclitaxel in Subjects With Platinum Resistant Ovarian Condition: Primary Peritoneal Carcinoma Date: 2013-09-18 Interventions: Drug: Demcizumab administered |
Recruiting |
Study Name: A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Condition: Ovarian Neoplasms Peritoneal Neoplasms Fallopian Tube Neop Date: 2013-05-01 Interventions: Drug: Trabectedin 1.1 mg/m2 ad |
Completed |
Study Name: Prevalence of HbA1C in Women With PCOS Condition: Polycystic Ovarian Syndrome Pelvic Endometriosis Insulin R Date: 2013-04-15 |